Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes

RET-selective tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib have revolutionized the landscape of RET-positive (RET+) advanced non-small cell lung cancer (NSCLC) treatment, thanks to their efficacy and safety profiles. This class of medications currently represents the standard of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocco, Danilo, Sapio, Luigi, Della Gravara, Luigi, Naviglio, Silvio, Gridelli, Cesare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916548/
https://www.ncbi.nlm.nih.gov/pubmed/36768754
http://dx.doi.org/10.3390/ijms24032433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916548/
https://www.ncbi.nlm.nih.gov/pubmed/36768754
http://dx.doi.org/10.3390/ijms24032433

Ejemplares similares